Compare CIVB & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIVB | ZVRA |
|---|---|---|
| Founded | 1884 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 591.5M | 562.2M |
| IPO Year | 2012 | 2015 |
| Metric | CIVB | ZVRA |
|---|---|---|
| Price | $28.82 | $11.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $26.60 | $23.00 |
| AVG Volume (30 Days) | 104.9K | ★ 1.4M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | 31.34 | ★ 159.21 |
| EPS | ★ 1.41 | 0.74 |
| Revenue | $19,023,000.00 | ★ $106,470,000.00 |
| Revenue This Year | $14.88 | $37.27 |
| Revenue Next Year | $5.99 | $53.42 |
| P/E Ratio | $20.18 | ★ $15.32 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $19.67 | $7.16 |
| 52 Week High | $29.97 | $15.04 |
| Indicator | CIVB | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 53.98 | 50.10 |
| Support Level | $26.21 | $8.26 |
| Resistance Level | $29.31 | $12.06 |
| Average True Range (ATR) | 0.59 | 0.51 |
| MACD | -0.12 | 0.18 |
| Stochastic Oscillator | 36.00 | 73.60 |
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agricultural, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. The majority of its revenues are derived from the interest and fees gained on loans.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.